Myriad Genetics Inc. (MYGN)
MYGN trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/899923/000089992326000018/0000899923-26-000018-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MYGN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | United States |
| IPO year | 1995 |
| SEC CIK | 0000899923 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $824.5M |
| Net income | -$365.9M |
| Operating income | -$387.2M |
| Net margin | -44.4% |
| Operating margin | -47.0% |
| Revenue growth | -1.6% |
| Cash | $149.6M |
| Total assets | $706.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-06 |
| Cash and burn | $107.1M cash; operating cash flow -$5.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 95,922,196 (2026-10-30); 93,213,722 a year earlier; 82,198,203 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-02-24 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Salt Lake City, Utah, United States | PCAOB Form AP 2026-03-11 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $722K, sold $67K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-09-30 | $202.7M | -$43.9M | -$6.5M | $107.1M | $121.1M | $803.6M | 10-Q 2026-11-06 |
| Q4 2026 2026-06-30 | $190.7M | -$43.2M | -$8.3M | $115.2M | $120.7M | $806.6M | 10-Q 2026-07-31 |
| Q3 2026 2026-03-31 | $200.4M | -$34.1M | -$15.7M | $124.4M | $120.3M | $829.0M | 10-Q 2026-05-06 |
| Q2 2026 2025-12-31 | $209.8M | -$7.9M | $10.6M | $149.6M | $119.9M | $824.5M | 10-K 2026-02-24 |
| Q1 2026 2025-09-30 | $205.7M | -$27.4M | $21.1M | $145.4M | $119.5M | $825.3M | 10-Q 2026-11-06 |
| Q4 2025 2025-06-30 | $213.1M | -$330.5M | -$13.6M | $74.4M | $59.4M | $832.9M | 10-Q 2026-07-31 |
| Q3 2025 2025-03-31 | $195.9M | -$100K | -$16.3M | $91.8M | $59.3M | $831.3M | 10-Q 2026-05-06 |
| Q2 2025 2024-12-31 | $210.6M | -$42.5M | $6.6M | $102.4M | $39.6M | $837.6M | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-03-04 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-11-06 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-14 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.4% |
| 1 month | +38.7% |
| 3 months | +78.5% |
| Year to date | -8.0% |
| 1 year | -10.9% |
| From 52-week high | -28.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NNNN | Anbio Biotechnology | $3.88 | +1.57% | $558.3M |
| TKNO | Alpha Teknova Inc. | $7.77 | -5.36% | $488.8M |
| QUIT | Achieve Life Sciences Inc. Common Shares | $6.06 | -4.11% | $666.8M |
| QDEL | QuidelOrtho Corporation | $10.21 | -4.93% | $700.5M |
| NTLA | Intellia Therapeutics Inc. | $9.86 | +1.65% | $1.4B |
| CLDX | Celldex Therapeutics Inc. | $28.59 | -0.83% | $2.2B |
| NEOG | Neogen Corporation | $10.88 | -3.12% | $2.4B |
| ICCC | ImmuCell Corporation | $11.42 | +6.23% | $103.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier